Genflow Biosciences Share Discussion Threads

[moneymunch] 04/10/2024 06:17

Boom.....52% UP!!!! Fingers crossed the UK will follow the US, and all eyes on the US OTC Markets when they open at 1pm as well as here at 8am....... Gla holders....On and UP!!!! ;-)

[moneymunch] 03/10/2024 21:42

OTC market UP 52% courtesy of Porter on Lse....Gla holders and fingers crossed for a surge of US interest from those in the know...On and UP!!! :-)

[moneymunch] 01/10/2024 06:24

As per Eric's interview, he hopes to bring news on several non-dilutive grant applications "very soon".....more cash to add to their coffers on its way!!! Gla ;-)

[prashaprash] 30/9/2024 21:16

The study aims to assess the production of clinical batches of GF-1002 in compliance with Good Manufacturing Practices. At the same time, the company is in the process of selecting contract research organisations to conduct an upcoming clinical trial in dogs for GF-1004, a simplified naked DNA version of its centenarian SIRT6 drug candidate.Likely next news will be about dog trial contract!

[bri15] 30/9/2024 19:05

At present spend rate funds will last well into next year,all we need now is some positive news on testing or FDA granting old age as a disease,

[moneymunch] 30/9/2024 18:22

More non-dilutive grant applications looking very promising and news expected very soon!!! Gla ;-)

[moneymunch] 30/9/2024 06:04

PRESS RELEASE



30 September 2024

Genflow Biosciences Plc



("Genflow" or "the Company")



HALF YEAR RESULTS





Genflow (LSE: GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.





Chairman's Statement



It is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on the Company's performance during the first six months of 2024.



Over the six months to 30 June 2024, the Company has made strides in its principal longevity programs: MASH (Metabolic Dysfunction-Associated Steatohepatitis) and Werner Syndrome.



In June, we updated shareholders on the momentum created with respect to our pre-clinical programs in MASH, and the guidance expected to be received from the FDA in the future. This guidance, which we anticipate receiving in the future, is expected to come through the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT), as a result of the Company submitting a comprehensive briefing package conducted with our lead drug candidate, GF-1002, for the treatment of MASH. In the meantime, the FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept ("POC") studies. Specifically, we have established a functional 3-D organoids of liver using cells from Werner patients. This organoid testing helps reduce the need for animal models in our scientific research. Organoids are miniature, lab-grown versions of human organs or tissues that mimic the structure and function of their real counterparts. By using these organoids, we can model human Werner Syndrome and better test response of our SIRT6 based gene therapy in a more human-relevant environment, rather than relying on unreliable animal models.



Additionally, we have initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). We are also in the process of selecting Contract Research Organizations (CROs) to conduct our upcoming dog clinical trial, aimed at studying our simplified Nake DNA version of our Centenarian SIRT6 drug candidate, GF-1004. We will provide updates in relation to our veterinary study in due course.



Over the period, we have also been working on two exciting collaborations supported by non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows;



· Sarcopenia research program with Revatis SA - focusing on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness.



· Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases.



During the period, the Company has received grant funding of totalling €777,281 in respect of these projects, with further financial support committed in the first half of 2025.



In addition, Genflow Biosciences SRL, received €350,000 in April 2024, from the regional government of Wallonia - Belgium Service Public de Wallonie, representing the second tranche of this awarded grant recognised in the previous year, 2023.



Further strengthening the Company's financial position and increasing its institutional investor base, the Company completed a placing and subscription to which raised £715,000 (before expenses) during the period. We were privileged to have Premier Miton, a well-known UK institution, participate in this fundraise.



Financial Overview



As of 30 June 2024, the Group had cash reserves of £1,139,859 (31 December 2023: £683,974) which has been derived from equity fundraising of £663,600 (net of expenses) and the receipt of research and development grants of £664,219 (€777,281) and £299,145 (€350,000) The Company remains debt free.



Administration expenses for 30 June 2024 totalled £1,316,368 (30 June 2023: £815,477), which primarily consisted of research and development costs of £938,109 (30 June 2023: £415,157), legal and professional fees totalling £90,654 (30 June 2023: £103,366) and Directors' fees of £178,656 (30 June 2023: £178,783).



The significant jump in research and development costs for 2024 is in relation to the advancement of testing, which has transitioned to the in vivo stage, which is inherently more costly.



Other Comprehensive Income was charged with a translation gain of £8,652 upon converting the Subsidiary's results for the period to GBP.



Future



On behalf of the Board, I thank you for your continued support. Our commitment to pioneering therapeutic solutions for longevity has been strengthened by the support of our collaborative partners and promising feedback from the FDA during the six-months to 30 June 2024. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. We remain focused on our mission to improve healthspan, and I look forward to providing you with further updates as we progress through our work programs, including clinical dog trials.

[prashaprash] 24/9/2024 15:02

Will be surprised if aging termed as disease ?

[moneymunch] 24/9/2024 14:29

Yep, 3 months without an UPdate, and so good news could drop at anytime. Gl:-)

[bri15] 24/9/2024 13:03

Well whoever got the £12K rollover is hoping for news soon.

[bri15] 24/9/2024 12:25

Hopefully we got some soon moneymunch,and we are well overdue that's for sure.

[moneymunch] 23/9/2024 07:39

Some positive newsflow should help. Gl :-)

[moneymunch] 19/9/2024 20:21

Eric's presentation, courtesy of Porter on Lse. Gla :-)

Another great presentation by Eric which reaffirms the reasons why I'm invested. Proof of concept dog trial imminent which should take 6 months and Eric already has an interested Vet Partner in place by the sounds of it. Looking forward to increased market and investor interest as positive newsflow is delivered in the coming days and weeks. Gl ;-)

[moneymunch] 18/9/2024 14:07

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,727 followers
3h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s development pipeline has a number of exciting #SIRT6 treatments. Paired with a patent-pending safe & cost-effective exosome delivery system, #GENF is poised to make exciting advancements.

Stay tuned for updates on our clinical trials!

[moneymunch] 17/9/2024 18:58

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,724 followers
2h

💻 Virtual conference alert!

Catch Genflow Biosciences (LON:GENF) (OTCQB:GENFF) at the OTC Life Sciences Investor Forum this Thursday, September 19th @ 10:00 a.m. ET.

CEO Dr. Eric Leire will cover #GENF's latest developments, including its recent research on #SIRT6 and its implications for #MASH.

Join here:
Event Launch

[moneymunch] 17/9/2024 08:00

Hopefully not too long before full market appreciation as positive newsflow is delivered by Eric and his team. The previous Virtual Presentation 7/3/24 saw Jonathan Swann's 3% declaration a couple of weeks later followed by his 4.8% plus and the UK Institutional Investor, Premier Milton's 9% plus which was the catalyst for the rise in share price at that time, and so hopefully more of the same following this week's presentation, especially on the progress made and on the back of any significant news. Any interest from US Institutional investors would be a game changer. Anyways, looking forward to the next UPdate or two, in Eric we trust!!! Gla holders;-)

[moneymunch] 17/9/2024 06:15

Genflow Biosciences Plc to Present at the Life Sciences Investor Forum September 19th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

September 16, 2024 08:57 ET | Source: Virtual Investor Conferences

Share

LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (LSE:GENF OTCQB:GENFF), based in the UK, focused on pioneering gene therapies to decelerate the aging process, today announced that Dr Eric Leire, Chief Executive Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.

DATE: September 19th
TIME: 10:00 AM ET
LINK:https ://bit.ly/3XjDJkL
Available for 1x1 meetings: September 19

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About Genflow Biosciences Plc

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow’s clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

[moneymunch] 16/9/2024 10:05

Perfectly poised and primed as the free float becomes tighter and tighter. Gla holders:-)

[moneymunch] 10/9/2024 10:19

News from Eric and Co must be close imho, and buying volume and share price should be ticking UP in anticipation. Gla ;-)

[moneymunch] 08/9/2024 19:42

Dr Nir Barzilai is also the director of the Institute for Aging Research at the Albert Einstein College of Medicine amongst other things. Gl :-)



21 March 2024

Genflow Biosciences Plc

Announces Publication of a Key European Patent in Partnership with University of Rochester, New York, et al.

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce a significant milestone in its journey. Genflow's collaborative partners, including the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, have received confirmation that their European patent application was published today by the European Patent Office, bearing the reference number EP 4 338 267.

[moneymunch] 08/9/2024 19:41

SIRT6: The protein that talks the talk and walks the walk

Partner content

Nir Barzilai on keeping longevity research relevant to humans, developing gerotherapeutics and making the best decisions.

Last month, US-Israeli startup SIRTLab announced the appointment of leading geroscience researcher Dr Nir Barzilai as its Chief Medical Adviser, adding additional longevity kudos to a company founded by Boaz Misholi and Professor Haim Cohen, a world leader in research of SIRT6, who has seen over $40 million invested in his research.